These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 31367906)

  • 1. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
    Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodal metabolic tumour volume on baseline
    Alipour R; Bucknell N; Bressel M; Everitt S; MacManus M; Siva S; Hofman MS; Akhurst T; Hicks RJ; Iravani A
    J Med Imaging Radiat Oncol; 2021 Oct; 65(6):748-754. PubMed ID: 34318603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
    Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
    Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
    Unterrainer M; Taugner J; Käsmann L; Tufman A; Reinmuth N; Li M; Mittlmeier LM; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Manapov F
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1407-1416. PubMed ID: 34664091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
    Parlak C; Topkan E; Onal C; Reyhan M; Selek U
    Radiat Oncol; 2012 Mar; 7():37. PubMed ID: 22429939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.
    Iravani A; Turgeon GA; Akhurst T; Callahan JW; Bressel M; Everitt SJ; Siva S; Hofman MS; Hicks RJ; Ball DL; Mac Manus MP
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1869-1877. PubMed ID: 31190177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy-based
    Chen HHW; Su WC; Guo HR; Lee BF; Chiu NT
    Kaohsiung J Med Sci; 2019 Mar; 35(3):151-159. PubMed ID: 30887722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Survival with 18-Fluorodeoxyglucose Positron Emission Tomography-directed Therapy in Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis.
    Newman S; Bucknell N; Bressel M; Tran P; Campbell BA; David S; Haghighi N; Hanna GG; Kok D; MacManus M; Phillips C; Plumridge N; Shaw M; Wirth A; Wheeler G; Ball D; Siva S
    Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):163-171. PubMed ID: 33129655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of
    Lee JW; Seo KH; Kim ES; Lee SM
    Eur Radiol; 2017 May; 27(5):1912-1921. PubMed ID: 27590191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical Exchange Saturation Transfer MRI: Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients.
    Ohno Y; Yui M; Yamamoto K; Takenaka D; Koyama H; Nagata H; Ueda T; Ikeda H; Ozawa Y; Toyama H; Yoshikawa T
    J Magn Reson Imaging; 2023 Jul; 58(1):174-186. PubMed ID: 36971493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT.
    Pan Y; Brink C; Schytte T; Petersen H; Wu YL; Hansen O
    Medicine (Baltimore); 2015 Oct; 94(43):e1863. PubMed ID: 26512597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
    AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.